Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome
Recruiting now · Not applicable · Has a placebo group
Conditions studied: Covid19, Neurocognitive Dysfunction
In brief
Post-COVID-19 syndrome is an assembly of symptoms, following an infection with Coronavirus disease 2019 (COVID-19). The syndrome is characterized by cognitive impairment, fatigue, sleep disorders, smell and taste disorders, pain and more. This long-term sequela can last for months after recovering from the virus, and no treatment is known to date. The aim of this study is to compare the effect of HBOT vs. Sham on post COVID-19 syndrome
Key facts
- Study ID
- NCT04647656
- Run by
- Assaf-Harofeh Medical Center
- People needed
- 91
- Starts
- 2023-06-01
- Expected to finish
- 2027-12-31
- Last updated by the study team
- 2026-04-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age above 18 years
- Reported post COVID-19 cognitive deterioration that effect quality of life and persist at least 3 months after confirmed infection.
- Subject willing and able to read, understand and sign an informed consent
You may not qualify if…
- Inability to attend scheduled clinic visits and/or comply with the study protocol
- History of traumatic brain injury (TBI) or any other non COVID brain pathology
- Active malignancy
- Substance use at baseline
- Severe or unstable physical disorders or major cognitive deficits at baseline
- HBOT for any reason prior to study enrolment
- Chest pathology incompatible with pressure changes (including moderate to severe asthma)
- Ear or Sinus pathology incompatible with pressure changes
- An inability to perform an awake brain MRI
- Active smoking
Where it is running
- Assaf-Harofeh medical center — Ẕerifin, Israel (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.